Company

Horizon Therapeutics

Pharmaceutical intelligence for Horizon Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 0
Catalysts: 1
Assets: 1

Recent signals

No signals indexed for this entity yet.

Upcoming catalysts(1)

Earnings Catalyst

Horizon Therapeutics — Tepezza

Q2 earnings will reveal subcutaneous uptake and pricing dynamics post-IV cannibalization.

July 25, 2026 · Commercial

Regulatory activity

No signals indexed for this entity yet.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Tepezza →

Therapeutic areas

Rare Disease →

Indications

Thyroid eye disease (subcutaneous) →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.